IQWiG finds benefit for Edurant, none for Eviplera

The German Institute for Quality and Efficiency in Health Care (IQWiG) issued preliminary benefit assessments of HIV drugs Edurant rilpivirine and Eviplera emtricitabine/tenofovir/rilpivirine compared with Sustiva efavirenz plus base therapy. The agency said in one assessment there was a "substantial" degree of benefit for Edurant rilpivirine from Johnson & Johnson (NYSE:JNJ) in treatment-naive patients. However, IQWiG found no additional benefit for Eviplera in a separate assessment. The agency considered the dossier for Eviplera incomplete because Gilead Sciences Inc. (NASDAQ:GILD) did not carry out a required analysis of sub-groups and excluded a relevant study. Gilead was up $0.35 to $45.86 on Monday. ...